POSITIVE CHMP OPINION IN EU FOR SAXA/DAPA (SAXAGLIPTIN AND DAPAGLIFLOZIN) FOR ADULTS WITH TYPE-2 DIABETES AstraZeneca today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion, recommending the approval of saxa/dapa (saxagliptin and dapagliflozin) tablets for the treatment of adults with type-2 diabetes. The fixed-dose combination of saxagliptin and dapagliflozin has the potential to be the first DPP-4i/SGLT-2i combination product approved in Europe. Saxa/dapa is a fixed-dose combination of saxagliptin and dapagliflozin being developed as a treatment for patients with type-2 diabetes in adults aged 18 years and older. It is recommended to be indicated as a treatment to improve glycaemic control when metformin and/or sulphonylurea and one of the mono -components of saxa/dapa alone do not provide adequate glycaemic control, or when a patient is already being treated with the free combination of saxagliptin and dapagliflozin. The submission included data from three studies in type-2 diabetes. In two studies, the combination of dapagliflozin and saxagliptin with metformin resulted in statistically significant reductions in HbA1c in comparison to patients treated with placebo that required additional control to existing saxagliptin and metformin or dapagliflozin and metformin therapy. An additional study showed that the combination of dapagliflozin and saxagliptin added on to metformin resulted in statistically superior reductions in HbA1c in comparison to patients treated with dapagliflozin or saxagliptin alone added to metformin. In these trials, the safety profile of saxa/dapa was similar to the known safety profiles of saxagliptin and dapagliflozin. The CHMP's positive opinion will now be reviewed by the European Commission (EC), which has the authority to approve medicines for the European Union (EU). The final decision by the EC is expected in the coming months, and will be applicable to all 28 EU member countries plus Iceland, Norway and Liechtenstein. About AstraZeneca in Diabetes AstraZeneca is pushing the boundaries of science with the goal of developing life-changing medicines that aim to reduce the global burden and complications of diabetes. Our current portfolio consists of the three newest classes of non -insulin, anti-diabetic treatments that support individualised treatment approaches: SGLT-2 inhibitors, GLP-1 receptor agonists and DPP-4 inhibitors. As a strategic therapy area for the company, we are focusing our research and development efforts on diverse populations and patients with significant co -morbidities, such as cardiovascular disease, obesity, non-alcoholic steatohepatitis (NASH), and chronic kidney disease. Our commitment to diabetes is exemplified by the depth and breadth of our global clinical research programme. This commitment is advancing understanding of the treatment effects of our diabetes medicines in broad patient populations, as well as exploring combination treatment approaches to help more patients achieve treatment success earlier in their disease progression. Our ambition is to reduce the long-term impact of diabetes. About AstraZeneca AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology - as well as in infection and neuroscience. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com CONTACTS Media Enquiries Neil Burrows UK/Global +44 7842 350541 Vanessa UK/Global +44 7880 400690 Rhodes Karen UK/Global +44 7818 524012 Birmingham Jacob Lund Sweden +46 8 553 260 20 Michele US +1 302 885 2677 Meixell Investor Enquiries UK Thomas Kudsk +44 7818 524185 Larsen Nick Stone RIA, CVMD +44 7717 618834 Henry Oncology Finance +44 7788 354619 +44 7881 615764 Wheeler Craig Marks Christer ING, Consensus Forecasts +44 7827 836825 Gruvris US Lindsey CVMD, Oncology +1 240 543 7970 Trickett Mitch Chan Oncology +1 240 477 3771 Dial / Toll +1 866 381 7277 -Free Key: RIA - Respiratory, Inflammation and Autoimmunity, CVMD - Cardiovascular and Metabolic Disease, ING - Infection, Neuroscience and Gastrointestinal 27 May 2016 - ENDS -
POSITIVE CHMP OPINION IN EU FOR SAXA/DAPA POSITIVE CHMP
Top 10 Most Recent News Articles
RadianX Grabs $9M for Perovskite Solar Push
RadianX Making Waves with New Funding Diving headfirst into the clean energy scene, RadianX has snagged a hefty $9 million in fresh funding. Now, this isn't some chump change. We're talking about a solid push to get their perovskite photovoltaic modules off the ground and into widespread use. They've got financial backing from big players like SOSV and Twynam, spearheaded...
Continue Reading
Coinhub Funded's Bold Move in Trading World
A New Name in the Trading Game Right out of Charlestown, Saint Kitts and Nevis, Coinhub Funded is making waves in the crypto prop trading world, and boy, they're not pulling any punches. They've just thrown their hat in the ring with a tantalizing offer: get your hands on a funded trading account up to $200K, and if that's not enough to get your pulse racing, they've got...
Continue Reading
Rice Sets Course in Houston’s Thriving Innovation Hub
Houston's Innovation Scene Expands The ground's barely settled and already Rice University is shaking up the scene in Houston’s Ion District with the Arc. At nearly 200,000 square feet, this powerhouse is set to bridge the gap between research, industry, and entrepreneurs, pushing ideas from discovery to reality. A Groundbreaking Investment For anyone with half an idea...
Continue Reading
PJM Prepares to Tackle Winter Power Demands
Eyeing the Season Ahead The chill in the air isn't just meteorological; there's a business note to notice every winter in PJM's sprawling territory. With power supplies robust yet stretched thin, PJM is bracing to navigate another demanding cold season. They’ve announced they have 182,426 MW of operational capacity nipping at the heels of a projected peak demand of...
Continue Reading
Elanco Surges with Solid Q3, Raises 2026 Forecast
Strong Q3 Performance Ignites Elanco's Growth Now here's a headline: Elanco's numbers are charging like a bull on steroids. Revenue surged 11% year-over-year to hit a cool $1.265 billion, showing off a 9% organic constant currency growth. And why should we, the investors, care? Because they've adjusted their EBITDA margin upwards to 19.5%, an impressive 2% boost from the...
Continue Reading
Gerstle Snelson Grabs Top Ranks in 2027 Best Law Firms
Big Wins on the Legal Stage When it comes down to the concrete jungle of construction law, Gerstle Snelson, LLP isn't just laying bricks; they're building skyscrapers. This Texas-based firm has secured three Regional Tier 1 rankings in the 2027 Best Law Firms® list. That's enough to make any law outfit puff out its chest a bit. What's in the Rankings? These rankings...
Continue Reading
UN's AI Toolbox Aims to Keep City Oversight Human
Artificial Intelligence: Tool or Tyrant? Ever feel like we're on a runaway train with this AI business in city management? The United Nations seems to think so, and it’s stepping in with a big red STOP sign—or rather, a toolbox. This week, in a grand procession at Barcelona's Smart City Expo, they rolled out the United for Smart Sustainable Cities (U4SSC) Toolbox,...
Continue Reading
Segway Powersports Pushes Deeper Into European Markets
Riding the Waves of European Market Expansion Segway Powersports, the adrenaline junkie's friend in motorsports, is cranking up its presence in Europe. Fresh off their annual International Business Partner Conference at EICMA 2026 in Milan, they’re not just talking shop. They've got a whole plan set to muscle in deeper into the European market with a new lineup for...
Continue Reading
TDS Hits Bumps but Keeps Shareholders Happy
High Hopes and Hard Hits: TDS in 2026 Listen up, folks. Telephone and Data Systems, Inc. (NYSE: TDS) just popped the hood on their third quarter earnings, and it's a mixed bag with plenty to chew over. Operating revenues are slightly down from last year, but management's got some tricks up their sleeves. CEO Walter Carlson is trumpeting their expanded fiber service...
Continue Reading
SM Investments Wins Five Golden Arrows: Governance on Point
Gold Arrows and Golden Standards What’s in a bunch of gold arrows, you might ask? Well, for SM Investments Corporation, those Five Golden Arrows from the Institute of Corporate Directors aren't just shiny trinkets. They're badges of honor, symbols of a rock-solid governance fortress. For the third year running, they’ve nailed the top spot under the corporate...
Continue ReadingTop 5 Most Recently Viewed Articles
Introducing the Innovative Direct Shaft Grinder Wheel Tool
Introducing the New Direct Shaft Grinder Wheel Tool Innovation has long driven progress in mechanical tools, and the introduction of the Direct Shaft Grinder Wheel Tool promises to transform the landscape of grinding equipment. An inventor from Scott, La., envisioned a more efficient way to tackle the challenges associated with traditional grinder wheel tools, leading to...
Continue Reading
Allot Partners with Play for Advanced Cybersecurity Service
Allot's Strategic Collaboration with Play for Cybersecurity In a groundbreaking development, Allot Ltd. (NASDAQ: ALLT, TASE: ALLT) has partnered with Play, a leading converged operator in Poland, to bolster cybersecurity for its fixed broadband customers. This strategic collaboration aims to deliver state-of-the-art security solutions through the introduction of DNS...
Continue Reading
Harnessing Aluminum Recycling for Economic Resilience
The Economic Significance of Aluminum Recycling Aluminum recycling goes beyond merely reusing materials; it serves as a significant catalyst for economic growth, supply chain robustness, and environmental stewardship. At Novelis, we recognize the immense importance of recycling aluminum for crafting a sustainable future. Creating Jobs and Boosting the Economy The aluminum...
Continue Reading
Florida's Insurance Crisis After Recent Hurricanes: What to Know
Understanding Florida's Insurance Market Crisis Florida's insurance landscape has been rocked by the recent devastating effects of hurricanes. With the occurrence of severe storms like Helene and Milton, the state is facing significant repercussions. Insurers are grappling with rising claims, soaring premiums, and an overall unstable market. The Storm Impact Following...
Continue Reading
BioCare Surges on Inc. 5000: Specialty Drug Wins
Bouncing Higher on Inc. 5000 Jaws were dropping this August when BioCare muscled its way up the Inc. 5000 list to hit No. 2520. That's a beastly leap, folks, bumping up 1,145 spots from the previous year. If you’ve got your ear tuned to the private sector, you know hitting this list for four years solid is no fluke, nor something to brush off. But it's not just about...
Continue Reading